NCT01910012已完成2 期
Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Polaris Group6 个研究点 分布在 2 个国家目标入组 43 人开始时间: 2015年1月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 6
- 主要终点
- Response Rate
研究概览
简要总结
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute myeloid leukemia (AML) diagnosed by morphologic, histochemical or cell surface marker criteria.
- •Patients with AML must have either:
- •(a) relapsed or refractory leukemia after receiving at least one prior conventional induction therapy. Those in early first relapse must not have a matched donor and/or they must not be a candidate for allogeneic stem cell transplantation (usually this would mean the patient is too ill, obese, has a co-morbid condition or is over the age of 55 years) or (b) poor-risk AML as defined below: (i) Treatment related AML, except if it is associated with favorable cytogenetics (e.g., inversion 16, t(16;16), t(8;21), t(15;17), and not a candidate for stem cell transplantation, or (ii) AML with an antecedent hematologic disease (e.g., MDS, myelofibrosis, polycythemia vera, etc.), and not a candidate for stem cell transplantation.
- •(iii) De novo AML > 70 years of age. (iv) AML with unfavorable cytogenetics regardless of age (>18 years), if patients are not candidates for allogeneic transplantation. Unfavorable cytogenetics are the following: complex (>3 abnormalities), -7, -5, 7q-, 5q-, abnormalities of 11q23 excluding t(9;11), t(9;22), inversion 3, t(3;3), t(6;9).
- •(c) Patients older than 60 years of age who had AML (i.e., > 20% bone marrow blasts) and no prior therapy for AML
- •Age ≥ 18 years.
- •ECOG performance status of 0-
- •Post-menarche female subjects and male subjects must be asked to use appropriate contraception for both the male and female for the duration of the study. Subjects must agree to use two forms of contraception or agree to refrain from intercourse for the duration of the study. Females must not be pregnant at the start of the study, and a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study.
排除标准
- •Patients with infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study; patients on prophylactic antibiotics or antivirals are acceptable.
- •Pregnancy or lactation.
- •Expected non-compliance.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, psychiatric illness, social situations that would limit compliance with study requirements or DIC.
- •Subjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or≤ Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and investigator may be allowed upon agreement with both.
- •Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present in the opinion of the investigator will not affect patient outcome in the setting of current diagnosis.
研究组 & 干预措施
ADI-PEG 20
Experimental
arginine deiminase formulated with polyethlene glycol
干预措施: ADI-PEG 20 (Drug)
结局指标
主要结局
Response Rate
时间窗: 2 years estimated
次要结局
- Safety and tolerability(2 years estimated)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic TherapyNon-Hodgkin's LymphomaNCT01910025Polaris Group18
已完成
2 期
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular CarcinomaUnresectable Hepatocellular CarcinomaNCT02006030Polaris Group30
已完成
1 期
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic MelanomaCutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid TumorsNCT01665183Polaris Group8
已完成
1 期
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast CancerHER2 Negative Metastatic Breast CancerNCT01948843Polaris Group15
终止
1 期
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and CisplatinPleural Mesothelioma Malignant AdvancedPeritoneal Mesothelioma Malignant AdvancedNon-squamous Non-small Cell Lung CarcinomaUveal MelanomaSarcomatoid CarcinomaHepatocellular CarcinomaGliomaNCT02029690Polaris Group85